register

News & Trends - MedTech & Diagnostics

Zimmer Biomet and Device Technologies announce partnership in orthopaedics

Health Industry Hub | April 12, 2021 |

MedTech News: Zimmer Biomet and Device Technologies, both major powerhouses in musculoskeletal healthcare, today announced a partnership to improve orthopaedic patient outcomes across Australia and New Zealand.

Zimmer Biomet has appointed Device Technologies as an exclusive distributor in Australia and New Zealand for its Sports Medicine and Surgical product portfolios from 12 April 2021, with Foot & Ankle and Trauma product portfolios to follow on 31 May 2021.

“The partnership with Device Technologies underscores a new business model that focuses on Zimmer Biomet’s core strengths while leveraging Device Technologies’ distribution and support network for greater growth in the target product portfolios in Australia and New Zealand,” said Warren Ballinger, Zimmer Biomet’s ANZ President. “The Device Technologies network will provide Zimmer Biomet with greater market penetration across Sports Medicine, Surgical, Foot & Ankle and Trauma. It will allow us to focus more on our hip, knee, shoulder, elbow, CMFT, Spine and Early Intervention product ranges as well as our suite of technology-based solutions,” he added.

“Partnering with Zimmer Biomet is an exciting step forward for Device Technologies. We are confident in the shared values between the two companies and that Zimmer Biomet’s product offering will complement our orthopaedic product portfolio and service Device Technologies customers well,” said Mick Trevaskis, Device Technologies CEO. “It’s a partnership that will see both companies proceed well together into the future.”

With over 90 years in the industry, Zimmer Biomet continues to be a driving force in musculoskeletal healthcare. Its unwavering focus on the needs of patients and surgeons drives the innovative and technologically advanced product solutions they offer. By combining with the extensive orthopaedic partnership network and loyal customer base of Device Technologies, Zimmer Biomet intends to further consolidate and strengthen its presence and reputation in Australia and New Zealand.

With 28 years’ experience in the orthopaedic market in Australia and New Zealand, Device Technologies boasts a history of consistent sales success; in 2019 the Device Technologies orthopaedic business had over 55% market share in Sports Medicine in Australia.

Zimmer Biomet’s product offerings will complement Device Technologies’ holistic portfolio, encompassing advanced orthopaedic products and technologies, product education, dedicated technical service and thorough clinical support. At present, 85% of orthopaedic surgeons in Australia and New Zealand are Device Technologies customers and 80% of current orthopaedic registrars across the two countries have participated in educational courses through Device Technologies.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.